A rabbit model of acute bacteremia and sepsis caused by vancomycin-resistant Enterococcus faecium
Frontiers in Cellular and Infection Microbiology · 16.04.2026 · 16
DOI: 10.3389/fcimb.2026.1619290 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 16.04.2026. Verfasst von Karen Flores-Moreno und 3 weiteren Autor:innen. Beteiligte Einrichtung: Programa de Inmunología Molecular Microbiana, Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de M…. Hauptthemen laut MEDLINE: Disease Models, Animal, Enterococcus faecium, Bacteremia, Gram-Positive Bacterial Infections. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Sepsis
Abstract (Originalsprache)
Background
Vancomycin-resistant Enterococcus faecium (VREF) is a leading cause of nosocomial bacteremia, with mortality rates exceeding 60%. Current animal models lack translational relevance due to the divergence in immune systems between rodents and humans.
Objectives
To establish a rabbit model of Enterococcus faecium infection for evaluating therapeutic regimes, specifically monoclonal antibody (mAb) therapy.
Methods
We established a reproducible rabbit model of acute VREF bacteremia using New Zealand White rabbits ( n = 20) intravenously challenged with 1 × 10 9 CFU/g of VREF (strain E155). The animals were divided into three groups: uninfected controls ( n = 6), infected untreated ( n = 7), and infected treated with mAb 8AP ( n = 7). We histopathologically examined the kidneys, lungs, spleen, heart, and liver, and quantified bacterial loads. Plasma cytokine levels were measured to assess inflammatory responses.
Results
Infected untreated rabbits exhibited significant weight loss, sustained fever (>40 °C, peaking at 39h), and 20% mortality within 12h. Systemic bacterial dissemination was confirmed in all organs examined, with the spleen showing the highest bacterial load and the liver exhibiting the most severe histopathological damage (necrosis and suppurative inflammation). The mAb 8AP treatment significantly improved clinical outcomes: heart and respiratory rates decreased, and body weight increased compared with untreated infected rabbits. Cytokine profiling showed elevated levels of IL-6, IL-8, and IL-10, consistent with systemic inflammatory response syndrome (SIRS), with the mAb treatment showing a trend toward immune modulation.
Conclusions
This model successfully simulates human VREF bacteremia and demonstrates the therapeutic potential of mAb 8AP. The rabbit model provides a clinically relevant platform for evaluating novel immunotherapies for VREF infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Programa de Inmunología Molecular Microbiana, Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.
- Laboratorio de Microbioma, División de Investigación, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.
Zitieren
APA
Flores-Moreno, K., Arredondo-Hernández, R., Mayoral-Terán, C., & López-Vidal, Y. (2026). A rabbit model of acute bacteremia and sepsis caused by vancomycin-resistant Enterococcus faecium. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1619290
Vancouver
Flores-Moreno K, Arredondo-Hernández R, Mayoral-Terán C, López-Vidal Y. A rabbit model of acute bacteremia and sepsis caused by vancomycin-resistant Enterococcus faecium. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1619290
BibTeX
@article{FloresMoreno2026,
author = {Flores-Moreno, Karen and Arredondo-Hernández, René and Mayoral-Terán, Claudia and López-Vidal, Yolanda},
title = {A rabbit model of acute bacteremia and sepsis caused by vancomycin-resistant Enterococcus faecium},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1619290}
}
EUVIMED